课题基金 / 基金详情

Developing diagnostics and therapeutics for preeclampsia: targeting a novel placental specific sFlt-1 variant

Developing diagnostics and therapeutics for preeclampsia: targeting a novel placental specific sFlt-1 variant
开发先兆子痫的诊断和治疗方法:针对新型胎盘特异性 sFlt-1 变体
批准号:
nhmrc : 1061977
负责人:
Dr Kirsten Palmer
金额:
$48.16万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2014
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2014-01-01 至 2016-12-31

项目摘要

项目成果

Dr Kirsten Palmer的其他基金

相似基金

相关文献

中文摘要
翻译
先兆子痫是一种可怕的妊娠期疾病,在全球范围内导致数千名母亲和婴儿死亡。它是由一种名为sflt-1的蛋白质从胎盘泄漏并攻击母亲的器官引起的。最近,一种新的sFlt-1亚型被发现,该亚型是针对胎盘的。这可能是导致子痫前期产生毒素的关键疾病。我们将以这种胎盘特异性sflt-1为靶点,产生诊断方法来预测先兆子痫,并探索新的方法来阻断sflt-1的毒性效应,作为开发药物的策略。
英文摘要
Preeclampsia is a dreaded disease of pregnancy, globally responsible for thousands of deaths of mothers and babies. It is caused by a protein called sFlt-1 leaking out of the placenta and attacking the mothers organs. Recently, a new sflt-1 subtype was discovered that is specific to the placenta. It may be the key disease causing toxin in preeclampsia. We will target this placental specific sFlt-1 to generate diagnostics to predict preeclampsia, and explore novel ways to block the toxic effects of sFlt-1 as a strategy to develop drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The development of therapeutics for pre-eclampsia.
  • 批准号:
    nhmrc : 607219
  • 项目类别:
    NHMRC Postgraduate Scholarships
  • 资助金额:
    $7.93万
  • 财政年份:
    2010
  • 负责人:
    Dr Kirsten Palmer
  • 依托单位:
海外基金